目的:预测人宫颈癌基因(human cervical cancer oncogene,HCCR)蛋白的二级结构,B细胞表位及其HLA-A,B限制性细胞毒性T细胞表位.方法:综合分析二级结构、亲水性、柔韧性、表面可及性与抗原性指数,预测HCCR蛋白的B细胞抗原表位;利用BIMAS,SYFPEITHI和NetCTL方法预测分析其HLA-A*0201限制性CTL表位,运用NetCTL方法对HLA-A的其他等位基因和HLA-B限制性CTL表位进行预测分析.结果:HCCR蛋白的二级结构主要由α-螺旋结构组成,B细胞优势表位位于N端第41～53,216～228,310～325和355～360区段;预测得到5个HLA-A*0201限制性CTL优势表位分别为YLVFLLMYL(152～160),YLFPRQLLI(159～167),LLLHNVVLL(343～351),CLFLGIISI(138～146)和SIPPFA-NYL(145～153),HCCR蛋白HLA-A,B限制CTL表位主要位于胞外区.结论:应用多参数预测HCCR蛋白B细胞表位及其HLA-A,B限制性细胞毒性T细胞表位,为进一步实验鉴定其表位进而制备单克隆抗体和基于HCCR抗原的肿瘤免疫学治疗奠定了基础.
Gene-silencing siRNA has shown great promise for the treatment of genetic diseases,cancers,and viral infections,but its therapeutic value has been hindered by the lack of an efficient and safe in vivo delivery system to target specific cells.The motor pRNA of phi29 has a strong tendency to form dimers,trimers and hexamers by interaction of interlocking right and left hand loops.This unique feature makes pRNA an ideal vector for the delivery of multiple therapeutic RNAs.Toxicity of pRNA was detected by transfection of 8 pRNA in HeLa cells.A pRNA-based vector was designed to carry siRNAs to inhibit GFP or HBV surface gene expression.Silence effects on siRNA against expression of GFP or HBV surface gene were detected in HeLa cells.Viral replicative intermediates were detected by Southern blotting.The results of toxicity study showed there was no toxicity of pRNA to cultured monolayer cells.The siRNA connected with pRNA can inhibit GFP or HBV surface gene expression in HeLa cells and inhibit HBV replication in HepG2 cells.These data suggest that pRNA can be used as a vector for imparting stability to siRNA in vitro.
To better understand the effect of a new split variant of human asialoglycoprotein receptor (ASGPR H1b) on ASGPR ligands' binding ability, we established a functional cell line which expresses ASGPR.The full lengths of ASGPRH1a and H2c fragments from human liver were amplified by reverse transcript PCR (RT-PCR) and inserted into eukaryotic expression vector pIRES2EFP, pCDNA3.1 (Zeo+) respectively.The recombinants were cotransfected into HeLa cells.After selection by using Neocin and Zeocin, a stably transfected cell line was established, which was designated 4-1-6.The transcription and expression of ASGPRH1a and H2c in 4-1-6 were confirmed by RT-PCR, Western blotting and immunofluorescence.The endocytosis function of the artificial "ASGPR" on the surface of 4-1-6 was tested by FACS.It was found that the cell line 4-1-6 could bind ASGPR natural ligand molecular asialo-orosomucoid (ASOR).After the eukaryotic plasmid H1b/pCDNA3.1 (neo) was transfected into cell line 4-1-6, H1b did not down-regulate the ligand binding ability of ASGPR.The eukaryotic expression plasmid H1b/pcDNA3.1 (neo) and H2c/pcDNA3.1 (neo) were co-transfected transiently into Hela cell.Neither single H1b nor H1b and H2c could bind ASOR.In conclusion, a functional cell line of human asialoglycoprotein receptor (ASGPR) which expresses both H1a and H2c stably was established.The new split variant H1b has no effect on ASGPR binding to ASOR.ASGPRH1b alone can't bind to ASOR, it yet can't form functional complex with ASGPRH2c.
Long-term compliance with regular surveillance is important for the prevention and timely management of chronic hepatitis B (CHB). However, there are no researches focusing on the compliance of hepatitis B virus infected patients in regular surveillance so far. The purpose of our study was to investigate the outpatient compliance with long-term regular surveillance in China. Data of 3257 CHB outpatients was pooled and analyzed to assess the outpatient's compliance with the long-term regular surveillance plan. In all outpatients, the non-follow-up and the follow-up group accounted for 73.2% and 26.8%, respectively. Among the follow-up outpatient's, only 48.9% received ongoing-follow-up and 51.1% were finally lost to follow-up; the median length of visiting duration was 25 months; and the predictive 1-, 2-, 3-, 4and 5-year ongoing follow-up rate was 72.7%, 52.5%, 42.4%, 33.8%, and 26.3%, respectively. In conclusion, our survey proved that the regular long-term surveillance on Chinese chronic HBV carrier is difficult to be fully implemented. A large proportion of outpatients do not receive routine follow-up and are at risk of treatment delay due to various social reasons.
Chronic hepatitis B virus(CHB) is currently treated with either interferon-based or nucleot(s)idebased antiviral therapies.However,treatment with pegylated interferon alpha results in a durable antiviral response in only about 30%patients and is associated with side effects.Most patients receiving nucleot(s)ide analogue treatment do not establish long-term,durable control of Infection and have rebounding viremia after cessation of therapy.Thus,novel therapy strategies are necessary to achieve the induction of potent and durable antiviral immune responses of the patients which can maintain long-term control of viral replication.Therapeutic vaccination of HBV carriers is a promising strategy for the control of hepatitis B.Here the authors review new therapeutic vaccination strategies to treat chronic hepatitis B which may be introduced for patient treatment in the future.
